0001209191-20-045935.txt : 20200810 0001209191-20-045935.hdr.sgml : 20200810 20200810161944 ACCESSION NUMBER: 0001209191-20-045935 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200806 FILED AS OF DATE: 20200810 DATE AS OF CHANGE: 20200810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kewalramani Reshma CENTRAL INDEX KEY: 0001735944 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 201089633 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS, INC. STREET 2: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-08-06 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001735944 Kewalramani Reshma C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2020-08-06 4 M 0 1564 187.53 A 28190 D Common Stock 2020-08-06 4 M 0 509 155.57 A 28699 D Common Stock 2020-08-06 4 S 0 152 269.11 D 28547 D Common Stock 2020-08-06 4 S 0 870 270.36 D 27677 D Common Stock 2020-08-06 4 S 0 471 271.42 D 27206 D Common Stock 2020-08-06 4 S 0 487 272.76 D 26719 D Common Stock 2020-08-06 4 S 0 93 273.27 D 26626 D Stock Option (Right to Buy) 187.53 2020-08-06 4 M 0 1564 0.00 D 2029-02-05 Common Stock 1564 15642 D Stock Option (Right to Buy) 155.57 2020-08-06 4 M 0 509 0.00 D 2028-02-05 Common Stock 509 3058 D Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $269.11 (range $268.69 to $269.59). Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $270.36 (range $269.90 to $270.85). Open market sales reported on this line occurred at a weighted average price of $271.42 (range $270.97 to $271.88). Open market sales reported on this line occurred at a weighted average price of $272.76 (range $272.25 to $272.99). The option vests in 16 quarterly installments from 02/06/2019. The option vests in 16 quarterly installments from 02/06/2018. /s/ Sabrina Yohai, Attorney-in-Fact 2020-08-10